Structure Therapeutics Announces $300 Million Private Placement Equity Financing
29. September 2023 07:32 ET
|
Structure Therapeutics Inc.
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds, along with existing cash, cash equivalents...
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
29. September 2023 07:30 ET
|
Structure Therapeutics Inc.
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight loss at 28 days supporting once-daily...
Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
10. August 2023 16:05 ET
|
Structure Therapeutics Inc.
Completed enrollment in 12-week Phase 2a study of oral GLP-1 receptor agonist, GSBR-1290 Topline data from Phase 2a and Phase 1b multiple ascending dose study of GSBR-1290 expected in latter half of...
Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors
03. August 2023 17:32 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for...
Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions
07. Juni 2023 08:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, June 07, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small...
Structure Therapeutics to Present at Jefferies Healthcare Conference
31. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity
25. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
12-week Phase 2a and Phase 1b multiple ascending dose (MAD) topline results expected to be announced in latter half of fourth quarter 2023 Ethnobridging study initiated in Japanese individuals and...
Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference
18. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
SAN FRANCISCO and SHANGHAI, China, May 18, 2023 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule...
Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
11. Mai 2023 16:30 ET
|
Structure Therapeutics Inc.
Oral GLP-1 agonist GSBR-1290 advancing into Phase 2a study in type 2 diabetes and obesity Topline data from Phase 1b multiple ascending dose and Phase 2a studies of GSBR-1290 expected in second half...
Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
30. März 2023 16:30 ET
|
Structure Therapeutics Inc.
Completed dosing of Phase 1b study of oral GLP-1 agonist GSBR-1290Topline data from Phase 1b and Phase 2a studies of GSBR-1290 expected in 2H 2023Completed $185.3 million upsized initial public...